HCM
HUTCHMED (China) Limited
There isn't enough reported data to score HCM yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HCM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
HCM's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.1x | $2.63 | -82% |
| Current | 5.7x | $14.85 | — |
| Fair | 5.8x | $3.00 | -80% |
| Expensive | 67x | $34.83 | +135% |
Historical ranges are pointers, not guarantees.
HCM's PE is 5.7x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over HCM in the historical PE scenario, which offers more potential upside but is not a forecast.
HCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect HCM's losses to grow, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over HCM on the outlook, with more favorable earnings expectations.
HCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.52 | +1200% |
| Q2 2025 | $0.53 | +$0.57 |
| Q4 2024 | $0.04 | -67% |
| Q2 2024 | -$0.04 | +$0.01 |
| Q4 2023 | $0.12 | +$0.55 |
| Q2 2023 | -$0.05 | +$0.25 |
| Q4 2022 | -$0.43 | -$0.18 |
| Q2 2022 | -$0.30 | -$0.05 |
HCM has the edge over OSCR in the latest year-over-year earnings comparison.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
HCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $270.8M | -17% |
| Q2 2025 | $277.7M | -9.2% |
| Q4 2024 | $324.5M | +6.4% |
| Q2 2024 | $305.7M | -43% |
| Q4 2023 | $305.1M | +36% |
| Q2 2023 | $532.9M | +164% |
| Q4 2022 | $224.4M | +13% |
| Q2 2022 | $202M | +28% |
HCM's revenue has slid since its 2023 peak: $271M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +17 points |
| Q2 2025 | -1.3% | -22 points |
| Q4 2024 | -5% | +89 points |
| Q2 2024 | -9% | +88 points |
| Q4 2023 | -31% | +62 points |
| Q2 2023 | 21% | +112 points |
| Q4 2022 | -94% | +3.8 points |
| Q2 2022 | -97% | -24 points |
HCM's operating margin was −13% last quarter, up 17 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HCM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.4M | -90% |
| Q2 2025 | -$82.2M | -$32.2M |
| Q4 2024 | $32.5M | +$47.9M |
| Q2 2024 | -$49.9M | -125% |
| Q4 2023 | -$15.4M | +$184.3M |
| Q2 2023 | $202M | +$307.7M |
| Q4 2022 | -$199.7M | -$59.3M |
| Q2 2022 | -$105.6M | -$25.4M |
HCM has burned cash in most quarters: −$96M over the past year, against −$119M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
HCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +327K shares |
| 1 year | +0.4% | +3.7M shares |
| 3 years | +31% | +207M shares |
| 5 years | +46% | +273M shares |
HCM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $36.1M |
| Q4 2023 | — |
| Q2 2023 | $9.1M |
| Q4 2022 | — |
| Q2 2022 | $48.1M |
| Q4 2021 | $551,000 |
| Q2 2021 | $26.8M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -6.5x | Net Cash |
HCM has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
HCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 79.2 | Neutral |
HCM's weekly RSI is 59 (neutral) and its Stochastic is 79 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HCM PE vs Healthcare Sector
| Metric | HCM | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 46 | 29 | 17 pts above |
HCM has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.2 | 4.4% above |
| 20 week MA | $13.0 | 14% above |
| 50 week MA | $13.4 | 11% above |
| 100 week MA | $14.3 | 4% above |
| 200 week MA | $15.4 | 3.8% below |
HCM has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 3.8% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HCM on trend strength, trading above more of its moving averages.
HCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $29.5 | +16% |
| 2021 | $29.5 | $35.3 | +20% |
| 2022 | $35.3 | $14.0 | -60% |
| 2023 | $14.0 | $18.1 | +29% |
| 2024 | $18.1 | $14.3 | -21% |
| 2025 | $14.3 | $13.8 | -3.5% |
| 2026 YTD | $13.8 | $14.9 | +7.8% |
HCM has finished lower in three of the last six years. It's up 7.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HCM on returns for 2026, with the stronger performance.